SCHEMBL2838280

SCHEMBL2838280

Cc1cn(-c2ccc(Cl)cc2)c(=N)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.46
KMT2A Q03164 3/20 0.46
RAB9A P51151 3/20 0.46
GAA P10253 2/20 0.46
MEN1 O00255 2/20 0.46
ALOX15 P16050 2/20 0.46
NPC1 O15118 1/20 0.46
ALOX12 P18054 1/20 0.46
TSHR P16473 1/20 0.39
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PTGS2 P35354 1/20 0.37
MC4R P32245 1/20 0.35
OPRK1 P41145 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
GPR35 Q9HC97 1/20 0.35
POLB P06746 2/20 0.34
APOBEC3G Q9HC16 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2872842 0.74 HTT (0.41) MAPTKMT2ARAB9AGAAMEN1
SCHEMBL4231575 0.74 POLB (0.40) MAPTRAB9AGAANPC1TSHR
SCHEMBL2873116 0.69 KMT2A (0.40) MAPTKMT2ARAB9AGAANPC1
Hydrochloric Acid SCHEMBL2836087 0.66 MAPT (0.53) MAPTKMT2ARAB9AGAAMEN1
SCHEMBL23727376 0.65 ALOX15 (0.44) MAPTKMT2ARAB9AGAAMEN1
SCHEMBL19365958 0.65 PTGS2 (0.53) MAPTGAAALDH1A1HPGDSMN1; SMN2
SCHEMBL22199034 0.63 PTGS2 (0.50) MAPTGAAALDH1A1HPGDSMN1; SMN2
SCHEMBL3975362 0.60 ALDH1A1 (0.67) MAPTKMT2ARAB9AGAAMEN1
SCHEMBL16474718 0.60 HPGD (0.44) MAPTKMT2ARAB9AMEN1ALOX15
Iodide SCHEMBL11212670 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245020-B1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBVIE INC (US) 2014-01-15 EP disclosed
US-8383657-B2 Thiazolylidine urea and amide derivatives and methods of use thereof ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
EP-2245020-A2 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF Abbott Laboratories (US) 2010-11-03 EP disclosed
WO-2009086163-A2 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-07-09 WO disclosed
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF ABBOTT LABORATORIES (US) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163470-A1 THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF NMUR1, NMUR2, PAM MAPT 465/4885KMT2A 2452/4885RAB9A 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.